Provention Bio (PRVB) Announces $125 Million Term Loan Facility with Hercules Capital
Don't think we've ever seen anything like this before. Most investors who prefer to invest post FDA approval, invest post FDA approval....
Revive (RVVTF) Hits a Snag?
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
First our summary."FDA provided communication that...
CB Scientific, Inc. (CBSC) Announces FDA 510(k) Submission.
CB Scientific, Inc. Announces FDA 510(k) Submission of Enhanced myCam Cardiac Event Monitor
Updated product to include significant...
OTC Markets Group Welcomes Direct Communication Solutions (DCSX), Inc. to OTCQX
NEW YORK, Dec. 16, 2020
NEW YORK, Dec. 16, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for...
Adding ‘Internet of Things,’ Direct Communications (DCSX) $1.17 to the Watch List.
Chris Bursey, Member of Verizon's Internet of Things (IOT) Advisory Council, Charges Ahead as CEO of Direct Communication (DCSX).
DCS (DCSX) Reports Strong Q2 Revenues and Growth
Highlights: 8.20.22
For the Quarter ending June 2022, Quarterly Revenues were reported at (Q2Revenue) USD $5.8 Million (CAD $7.5...
Revive Therapeutics (RVVTF) Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA
TORONTO, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
ARK vs. SARK
Ever get really, really bearish and really, really wish you could find a simple way to make money in a bear market?
MedAvail Announces Technology Partnership with Progressive Care, Inc (RXMD).
MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”) a technology-based retail pharmacy company, and Progressive Care Inc. (OTCQB: RXMD) ("Progressive Care”) a personalized healthcare...
Alzheimer Drug Trials
A winner is crowned in head-to-head Alzheimer's battle between Biogen's Aduhelm and Lilly - Dec 1, 2022
Eli...
Latest article
Institutional Analyst Newsletter. Citius (CTXR), GeoVax (GOVX.
DERBY WEEKEND - WE'RE HEADED TO TAMPA!HAT'S ON, DRINK'S UPADDING CITIUS PHARMA (CTXR) $0.66, TO WATCHLISTUPDATING GEOVAX LABS (GOVX) $1.43OUR $26...
Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.
Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!
Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.
CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...
